One explanation for this might be that the anti PD-L1 antibody avelumab leads to an early anti-tumor immune activation, thereby inducing high response rates, but this effect may be lost in the course of treatment e.g., through the emergence of immune escape variants as suggested earlier (14). This evidence concerns the gene CD274 and neoplasm.